I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
I Want to...
Saraswati Sukumar, Ph.D.
Professor of Oncology
Research Interests: Methylated genes as markers of breast cancer; Intraductal instillation for treatment of DCIS and prevention of breast cancer; HOX genes and their diverse oncogenic and tumor suppressor functions in breast cancer ...read more
- Professor of Oncology
- Professor of Pathology
Research & Publications
The research goal of the Sukumar laboratory is to obtain a molecular profile of breast cancer and to apply this knowledge to the early detection, diagnosis and therapy of breast cancer. Toward this end, SAGE, array, and proteomic analysis of breast carcinomas is being performed on noninvasive (ductal carcinoma in situ), invasive (invasive ductal carcinoma), and metastatic breast cancer (bone, ovarian, brain metastasis). The goal is to obtain mRNA and protein profiles of each cell type composing the lesion. This will help derive gene expression signatures typical for each stage of breast cancer for epithelial, stromal, and endothelial cells. By such careful analysis, candidate genes are identified, characterized and utilized for early detection and/or therapy of breast cancer.
Previous gene searches in breast cancer performed here identified a number of potential candidate tumor suppressors and oncogenes. These belonged to families of genes involved in a variety of functions in the cell. Transcription factors, such as HOXA5, WT1, RAR-beta and Twist; cell cycle regulators such as Cyclin D2 and 14.3.3 sigma; and tight junction proteins, such as Claudin-3, -4 and -7, were selected for further analysis. Biological analysis of these genes revealed molecular alterations that could lead to their aberrant function in breast cancer cells, results of which were published in the last three years. Hypermethylated promoter regions of a number of genes serve as tumor- specific markers for early detection of breast cancer. As described in a paper in Lancet in 2001, a marker panel consisting of Cyclin D2, RAR-beta and Twist was capable of detecting almost all breast cancers (96 percent) with a high level of specificity and sensitivity. This marker panel detected cancer in two high-risk women who were mammographically normal. This panel has now been improved by adding more markers, such as RASSF1A, HIN-1, ER-a and ER-b, and by developing a multiplex, quantitative methylation-specific PCR (Q-MSP). Q-MSP will allow accurate determination of the relative amount of methylation present in each gene, using less than nanogram amounts of DNA, in an objective manner. To test this premise, these markers are currently being applied to ductal cells obtained in two current trials aimed at validating the markers for early detection in high-risk women.
Soon, this panel will be tested as intermediate- response markers in a chemoprevention trial in collaboration with three other institutions in the United States. A combination of an objective test, such as MSP, with a subjective test, such as cytology, has the potential to provide an adjunct to mammography for early detection of breast cancer. This test is also being modified to detect tumor-specific DNA in serum from breast cancer patients.
The long-term goal is to provide a molecular blood test for early detection of breast cancer. Interrogating the hypothesis that breast cancer can be treated and prevented by delivery of agents via the intraductal route, both conventional and novel agents were tested. First, treatment of rats bearing carcinogen-induced tumors with Doxil results in complete regression of the tumors. Doxil administration via this route in a prevention setting, soon after carcinogen administration, also protected 90 percent of the treated glands. This mode of delivery can achieve therapeutic effects with less than one-third the systemic dose of the drug. This concept has also been tested in the HER2/neu mouse model for breast cancer. Here again, potent antitumor effects on established tumors were achieved by intraductal instillation of Doxil. Doxil also prevented the development of mammary tumors in this system. With the goal of eliminating the primary tumor and its metastasis, chemotherapy is being combined with immunotherapy (in collaboration with the Jaffee laboratory). Targeting genes that were found by our previous SAGE analysis searches to be overexpressed in breast cancer (the Claudins 3 and 4), we are testing therapies using Clostridium perfringens enterotoxin (CPE). CPE binds to the overexpressed tight junction proteins Claudin 3 and 4 on the tumor cells, resulting in tumor cell kill. No apparent cytotoxic effects are observed on normal epithelial cells. Additionally, the systemic toxic effects of CPE on the gastrointestinal tract are bypassed by utilizing the intraductal route of delivery. A combination of basic and preclinical research efforts in the laboratory aims at translating discoveries made at the bench to the clinic as rapidly as possible.
Our lab is focused on using comprehensive gene expression, methylation and sequencing and metabolomics analysis to identify alterations in breast cancer, and exploiting these for early detection and therapy. Among differentially expressed genes, our lab has focused on the HOX genes. HOX genes are intimately involved in the development of resistance to both chemotherapy and to agents targeting the estrogen receptor. Our work explores the alternate pathways that are activated by HOX proteins leading to this resistance and novel treatments to overcome resistance in both tissue culture and xenograft models. In addition, epigenetically silenced genes and a metabolic reprogramming in tumors also trigger novel early detection and therapeutic strategies. We are testing the utility of differentiation therapy through reactivating RAR-beta in breast cancer using histone deacetylase inhibitors with great success. Also, we are targeting enzymes involved in gluconeogenesis and glycolysis with small molecule FDA-approved antimetabolites to achieve antitumor effects.
Selected PublicationsView all on Pubmed
Teo WW, Merino VF, Cho S, Korangath P, Liang X, Wu RC, Neumann NM, Ewald AJ,Sukumar S. HOXA5 determines cell fate transition and impedes tumor initiation and progression in breast cancer through regulation of E-cadherin and CD24. Oncogene.2016 May 9. doi: 10.1038/onc.2016.95. PubMed PMID:27157614.
Jin K, Park S, Teo WW, Korangath P, Cho SS, Yoshida T, Győrffy B, Goswami CP, Nakshatri H, Cruz LA, Zhou W, Ji H, Su Y, Ekram M, Wu Z, Zhu T, Polyak K, Sukumar S. HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance. Cancer Discov. 2015 Sep;5(9):944-59. doi: 10.1158/2159-8290.CD-15-0090. Epub 2015 Jul 15. PubMed PMID: 26180042; PubMed Central PMCID: PMC4560624.
Fackler MJ, Lopez Bujanda Z, Umbricht C, Teo WW, Cho S, Zhang Z, Visvanathan K, Jeter S, Argani P, Wang C, Lyman JP, de Brot M, Ingle JN, Boughey J, McGuire K, King TA, Carey LA, Cope L, Wolff AC, Sukumar S. Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer. Cancer Res. 2014 Apr 15;74(8):2160-70. doi: 10.1158/0008-5472.CAN-13-3392. Erratum in: Cancer Res. 2014 Jun 1;74(11):3196. PubMed PMID: 24737128; PubMed Central PMCID: PMC4327879.
Stearns V, Mori T, Jacobs LK, Khouri NF, Gabrielson E, Yoshida T, Kominsky SL, Huso DL, Jeter S, Powers P, Tarpinian K, Brown RJ, Lange JR, Rudek MA, Zhang Z, Tsangaris TN, Sukumar S. Preclinical and clinical evaluation of intraductally administered agents in early breast cancer. Sci Transl Med. 2011 Oct 26;3(106):106ra108. doi: 10.1126/scitranslmed.3002368. PubMed PMID: 22030751;PubMed Central PMCID: PMC3616888.
Jin K, Kong X, Shah T, Penet MF, Wildes F, Sgroi DC, Ma XJ, Huang Y, Kallioniemi A, Landberg G, Bieche I, Wu X, Lobie PE, Davidson NE, Bhujwalla ZM,Zhu T, Sukumar S. The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2736-41. doi: 10.1073/pnas.1018859108. Epub 2011 Jun 20. PubMed PMID: 21690342; PubMed Central PMCID: PMC3286915.